Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma

Modern Pathology

Volumn 25, Issue 10, 2012, Pages 1378-1383

  Wang, Wei Lien ^a   Patel, Nimesh R ^b   Caragea, Mara ^c   Hogendoorn, Pancras C W ^d   López Terrada, Dolores ^b   Hornick, Jason L ^e   Lazar, Alexander J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ERG; Ewing sarcoma; EWSR1; FLI1; immunohistochemistry

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC2; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; EWING SARCOMA; GENE EXPRESSION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; TISSUE MICROARRAY; TISSUE SECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CELL NUCLEUS; CROSS REACTIONS; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; ONCOGENE PROTEINS, FUSION; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84867011997     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.97     Document Type: Article

References (31)

1. Gamberi G, Cocchi S, Benini S, et al. Molecular diagnosis in Ewing family tumors: the Rizzoli experience-222 consecutive cases in four years. J Mol Diagn 2011;13:313-324.
2. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 2011;204:351-365.
3. Zoubek A, Pfleiderer C, Salzer-Kuntschik M, et al. Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer 1994;70:908-913. (Pubitemid 24331085)
4. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-151. (Pubitemid 24188594)
5. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-5754. (Pubitemid 32928112)
6. Wang L, Bhargava R, Zheng T, et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn 2007;9:498-509. (Pubitemid 47434117)
7. Ng TL, O'Sullivan MJ, Pallen CJ, et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn 2007;9:459-463. (Pubitemid 47434112)
8. Szuhai K, Ijszenga M, de Jong D, et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 2009;15: 2259-2268.
9. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009;6:429-439.
10. Park K, Tomlins SA, Mudaliar KM, et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12:590-598.
11. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011;35:432-441.
12. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011;24:1128-1138.
13. Paulo P, Barros-Silva JD, Ribeiro FR, et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 2012;51:240-249.
14. Martens JH. Acute myeloid leukemia: a central role for the ETS factor ERG. Int J Biochem Cell Biol 2011;43:1413-1416.
15. Yi H, Fujimura Y, Ouchida M, et al. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997;14:1259-1268. (Pubitemid 27151983)
16. Kruse EA, Loughran SJ, Baldwin TM, et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc Natl Acad Sci USA 2009; 106:13814-13819.
17. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008;9:810-819. (Pubitemid 351859165)
18. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008;111:3498-3506.
19. Birdsey GM, Dryden NH, Shah AV, et al. The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood 2012;119:894-903.
20. Sperone A, Dryden NH, Birdsey GM, et al. The transcription factor Erg inhibits vascular inflammation by repressing NF-kappaB activation and proinflammatory gene expression in endothelial cells. Arterioscler Thromb Vasc Biol 2011;31:142-150.
21. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011;459:441-447.
22. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010;13: 228-237.
23. Folpe AL, Chand EM, Goldblum JR, et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 2001;25:1061-1066. (Pubitemid 32685904)
24. Rossi S, Orvieto E, Furlanetto A, et al. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol 2004;17:547-552. (Pubitemid 38868421)
25. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010;28: 1982-1988.
26. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000; 24:1657-1662.
27. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol 2001;9: 255-260. (Pubitemid 32783049)
28. Mhawech-Fauceglia P, Herrmann F, Penetrante R, et al. Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies. Histopathology 2006;49:569-575. (Pubitemid 44924288)
29. Mhawech-Fauceglia P, Herrmann FR, Bshara W, et al. Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol 2007;60:694-700. (Pubitemid 46975228)
30. Epitomics ITS. (e-mail communication from the Antibody manufacturer) 2012.
31. Ginsberg JP, de Alava E, Ladanyi M, et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999;17:1809-1814. (Pubitemid 29269251)